Fig. 6From: Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practiceOCT 1: Pre-RBZ, CMT of 445 μm; OCT 2: Post-RBZ: persistence of a small amount of fluid despite 3 monthly injections of RBZ, CMT of 301 μm; OCT 3: resolution of persistent fluid after switching to AFL, CMT of 216 μm. OCT ocular coherence tomography, RBZ ranibizumab, AFL aflibercept; CMT central macular thicknessBack to article page